Arch Biopartners (TSXV:ARCH) Change In Inventory : C$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Change In Inventory?

Arch Biopartners's change in inventory for the quarter that ended in Dec. 2023 was C$0.00 Mil. It means Arch Biopartners's inventory stayed the same from Sep. 2023 to Dec. 2023 .

Arch Biopartners's change in inventory for the fiscal year that ended in Sep. 2023 was C$0.00 Mil. It means Arch Biopartners's inventory stayed the same from Sep. 2022 to Sep. 2023 .

Arch Biopartners's Total Inventories for the quarter that ended in Dec. 2023 was C$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Arch Biopartners Change In Inventory Historical Data

The historical data trend for Arch Biopartners's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Change In Inventory Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Inventory

Get a 7-Day Free Trial

Arch Biopartners Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Arch Biopartners Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Arch Biopartners (TSXV:ARCH) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Arch Biopartners's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Arch Biopartners's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Arch Biopartners's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Arch Biopartners Change In Inventory Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners (TSXV:ARCH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.